Olives inhibit cancer cells growth and prevents their appearance
Run a fingertip over an unwashed olive and you pick up a faint waxy bloom. Inside that bloom sits maslinic acid — the compound behind twenty years of hopeful cancer headlines. It deserves an honest hearing rather than a hyped one.
Every olive wears a coat. That dull, slightly greasy bloom on the fruit before it is washed is a cuticular wax the tree builds to hold water in and fungi out, and it is chemically busy stuff. Two pentacyclic triterpenes dominate it: oleanolic acid and maslinic acid. Neither has much to do with flavour, and until the late 1990s almost nobody outside plant chemistry cared about them. Then laboratories in Andalusia, sitting on mountains of olive processing residue, started asking what was in the waste — and maslinic acid began appearing in headlines that promised rather more than the data behind them.
What maslinic acid actually is
It is a naturally occurring pentacyclic triterpene, a rigid five-ring molecule, present in the skin wax and leaves of Olea europaea and in a scattering of other plants. In an olive it is a defensive compound — a phytoalexin, in the jargon — not a nutrient. It is barely soluble in water, which matters enormously for anyone hoping to swallow it and have it do something. The largest practical reserves of it are not in the fruit you eat but in the residue left after oil extraction: pomace, or alpeorujo, the sludgy mix of skin, pulp, crushed stone and vegetation water that an olive mill produces in vastly greater quantity than oil. That is the whole commercial logic of the field. A mill’s biggest problem is what to do with its waste, and any compound that turns waste into a saleable extract is worth a research budget.
What the laboratory has shown
The published work is genuinely interesting and almost entirely preclinical. In cell culture, maslinic acid slows the proliferation of several cancer cell lines — colon cell lines have been studied most — and pushes those cells towards apoptosis, the orderly self-destruct programme that tumour cells characteristically evade. It also shows anti-inflammatory and antioxidant activity in the same kinds of assays, and animal studies have reported effects on inflammation, glucose handling and muscle metabolism. That is a respectable body of evidence for a plant compound, and it explains why the interest has not faded.
What it is not is evidence that eating olives prevents or treats cancer. A dish in an incubator is not a person. Compounds that look formidable against cells in a well have a long, sobering record of doing nothing measurable in a human body, most often because they never reach the tissue in question at a meaningful concentration. Maslinic acid’s bioavailability in humans remains poorly characterised, and the human trials that exist are few, small, and aimed at things like joint discomfort rather than tumours.
| Compound | Maslinic acid, a pentacyclic triterpene |
|---|---|
| Found in | Olive skin wax and leaves; concentrated in pomace (alpeorujo) |
| Role in the plant | Defensive surface compound, not a nutrient |
| Solubility | Very poor in water — a real obstacle to absorption |
| Evidence base | Mostly cell-culture and animal studies |
| Human evidence | Sparse; bioavailability not well established |
| Dietary relevance | Trace amounts in table olives and unfiltered oil |
Why the headlines keep coming back
Three things guarantee this story returns every few years. Olive-producing regions fund a great deal of olive research, and a positive finding is good regional news. Waste valorisation is real money, so extraction plants and patents follow the papers. And cancer prevention is the single most reliable way to get a plant compound into a newspaper. None of that makes the science dishonest — the laboratory work is real — but it does mean the gap between this molecule inhibits a colon cancer cell line and olives prevent cancer gets closed by headline writers rather than by researchers.
The sensible position is unglamorous. Olives and good olive oil belong in a diet that appears, on population-level evidence, to be a healthy one. That case rests on the whole pattern of eating — the fat profile, the vegetables, the pulses, what is being displaced — not on any single wonder molecule. Anyone selling you a supplement on the strength of an in vitro result is selling you the gap.
What it means at the table
- Table olives and unfiltered oil carry trace amounts of these triterpenes; brining and refining strip most of them.
- Olive leaf and pomace extracts are far richer than anything you eat — which is why supplements come from the waste stream, not the fruit.
- A cloudy, unfiltered oil carries more suspended skin and pulp material, and therefore more of this chemistry, but it also keeps less well.
- Treat any product promising a therapeutic dose of an olive triterpene with the scepticism you would apply to any supplement claim.
This is general information, not medical advice.
Maslinic acid and olives: common questions
What is maslinic acid?
A pentacyclic triterpene found in the waxy skin and leaves of the olive. It is a defensive plant compound rather than a nutrient, and it is most concentrated in olive processing residue.
Do olives prevent cancer?
No study shows that. Maslinic acid slows growth and triggers apoptosis in cancer cell lines in the laboratory, which is a long way from an effect in people. Human evidence is sparse.
Why is pomace the main source?
Because the compound sits in skin and pulp, and pomace is what remains after the oil has been pressed out. Mills produce it in enormous volumes, so extraction is economically attractive.
Is maslinic acid absorbed when you eat olives?
Poorly, as far as anyone can tell. It is barely water-soluble and its bioavailability in humans is not well characterised, which is the central weakness in the whole story.
Should I take an olive triterpene supplement?
There is no good human evidence to justify it. Eating olives and decent olive oil as part of a varied diet is a better-supported choice. This is general information, not medical advice.
I have watched this cycle three times now. A paper lands, a press office writes it up, and within a week someone is telephoning mills asking to buy alpeorujo by the lorry-load. Then the extraction economics get examined, the human data does not arrive, and the interest quietly evaporates — until the next paper. What has genuinely changed is that mills no longer think of pomace as pure liability, and that is a real gain. Just do not let it change what you believe about a bowl of olives.
Drawn from published research on olive triterpenes and on the composition of olive processing residue.